Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

NCT Number	NCT06950814
Lead Sponsor	West China Hospital
Conditions	Sarcomatoid Carcinoma, Liver Cancer, Adjuvant Therapy
Enrollment	50 participants
Start Date	2025-04-05
Primary Completion	2025-05-03 (estimated)
Study Completion	2025-05-05 (estimated)
Updated on ClinicalTrials.gov	2025-04-30